

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently amended) ~~A pharmaceutical~~ Pharmaceutical preparation that contains comprising:

(a) ~~at least one~~ an emulsifier that is PEG-40-hydrogenated castor oil (Cremophor<sup>®</sup>RH40), PEG-35 castor oil (Cremophor<sup>®</sup>EL) or PEG-400-monoricin oleate (Estax<sup>®</sup>54),

(b) ~~at least one~~ an auxiliary emulsifier and/or solvent that is glyceryl monocaprylate > 80% (m/m) (Imwitor<sup>®</sup>308) or diethylene glycol monoethyl ether (Transcutol<sup>®</sup>P) and

~~\_\_\_\_\_~~ (c) ~~as well as and at least one~~ a lipid that is a mid-chain triglyceride, fatty oil or wax,

~~characterized in that wherein~~ the mass ratio of emulsifier to auxiliary emulsifier and/or solvent (Smix) is 1:1 to 9:1 and the total lipid proportion is > 10-50 % (m/m), ~~whereby this preparation at least partially inhibits at least one intestinal enzyme and/or at least one intestinal efflux system.~~

2. (Currently Amended) ~~Pharmaceutical~~ A pharmaceutical preparation according to claim 1, wherein the Smix is 3:1 to 9:1.

3. (Currently Amended) ~~Pharmaceutical~~ A pharmaceutical preparation according to claim 3, wherein the Smix is 9:1.

4. (Currently Amended) ~~Pharmaceutical~~ A pharmaceutical preparation according to Claim 1, wherein the total lipid proportion the preparation contains 10-50% (m/v) a steroid.

5-8 (Cancel)

9. (Currently Amended) ~~Pharmaceutical~~ A pharmaceutical preparation according to claim 8, wherein the triglyceride contains mid-chain triglycerides (Miglyol<sup>®</sup>).

10. (Currently Amended) ~~Pharmaceutical~~ A pharmaceutical preparation according to claim 8, wherein the fatty oil ~~contains~~ comprises castor oil, olive oil, corn oil, soybean oil, sunflower oil, peanut oil, walnut oil or diestel oil.

11. (Currently Amended) ~~Pharmaceutical~~ A pharmaceutical preparation according to claim 8, wherein the wax ~~contains~~ comprises ethyl oleate or isopropyl myristate.

12-18 (Cancel)

19. (Currently Amended) ~~Pharmaceutical~~ A pharmaceutical preparation according to claim 18, wherein the steroid in 17-position of the sterane skeleton contains a secondary, beta-position hydroxyl group.

20. (Currently Amended) ~~Pharmaceutical~~ A pharmaceutical preparation according to Claim 1, wherein the steroid is an estrogen, an antiestrogen or an androgen.

21. (Currently Amended) ~~Pharmaceutical~~ A pharmaceutical preparation according to Claim 1, wherein the steroid is 11- $\alpha$ -hydroxynandrolone, 16- $\alpha$ -fluoroestradiol, 16- $\alpha$ -iodoestradiol, 16- $\beta$ -fluoroestradiol, 2,4-dibromoestradiol, 2-chloroestradiol, 2-ethoxyestradiol, 2-fluoroestradiol, 2-hydroxyestriol, 2-methoxyestradiol, 2-methoxyestriol, 2-methoxymethylestradiol, 3-methoxyestriol, 4-bromoestradiol, 4-chloroestradiol, 4-fluoro-17 $\beta$ -estradiol, 4-hydroxyestradiol, 4-hydroxytestosterone, 4-methoxyestradiol, 5- $\beta$ -androstane-17 $\beta$ -ol-3-one, 6- $\alpha$ -hydroxyestradiol, 3 $\alpha$ , 17 $\beta$ -androstenediol, 3 $\beta$ , 17 $\beta$ -androstenediol, androstanolone, androstenediol, bolanediol, bolazine, boldenone, clostebol, dacuronium bromide, 17-deacetylpancuronium, dideactetylvecuronium, vecuronium, 17 $\beta$ -dihydroequilin, 5 $\alpha$ -dihydro-19-nortestosterone, 16 $\alpha$ -bromo-7 $\alpha$ -(N-butyl, N-methyl-undecanamide)-estra-1,3,5(10)-triene-3,17 $\beta$ -diol, 16 $\alpha$ -chloro-7 $\alpha$ -(N-butyl, N-methyl-undecanamide)-estra-1,3,5(10)-triene-3,17 $\beta$ -



quinestradol, 17 $\beta$ -hydroxy-7 $\alpha$ -methyl-androst-5-en-3-one, 11 $\alpha$ -ethenyl-estra-  
 3, 17 $\beta$ -diol, 11 $\beta$ -[4(dimethylamino)phenyl]-estra-3, 17 $\beta$ -diol, 7 $\alpha$ -{4-[2-  
 (dimethylamino)ethoxy]phenyl}-estra-3,17 $\beta$ -diol, 11 $\beta$ -{4-  
 [(methylsulfonyl)oxy]phenyl}-estra-3,17 $\beta$ -diol, 11 $\beta$ -{4-[[5-[(4,4,5,5,5-  
 pentafluoropentyl)sulfonyl]pentyl]oxy]phenyl}-estra-3,17 $\beta$ -diol, 17 $\beta$ -  
 dihydroxy-9 $\alpha$ -fluoro-11 $\beta$ -androst-1,4-dien-3-one, stenbolone,  
 cycloprop[14R,15 $\alpha$ ]estra-3',15-dihydro-3-methoxy-1,3,5(10)-trien-17 $\beta$ -ol,  
 cycloprop[14S,15 $\beta$ ]estra-3',15-dihydro-3-methoxy-1,3,5(10)-trien-17 $\beta$ -ol,  
 testosterone, trestolone, trilostane, 13 $\beta$ -ethyl-8 $\alpha$ -gona-1,3,5(10)-triene-  
 3,16 $\alpha$ ,17 $\beta$ -triol, 13 $\beta$ -ethyl-8 $\beta$ -gona-1,3,5(10)-triene-3,16 $\alpha$ ,17 $\beta$ -triol, estra-2-  
 {tricyclo[3.3.1.1<sup>3,7</sup>]decyl}-1,3,5(10)-triene-3,17 $\beta$ -diol, ent-estradiol, 8 $\beta$ -  
 vinyl-estradiol, 11 $\beta$ -fluoro-7 $\alpha$ -{5-[N-methyl-N-3-(4,4,5,5,5-  
 pentafluoropentylthio)-propylamino]pentyl}-estra-1,3,5(10)-triene-3,17 $\beta$ -diol,  
 11 $\beta$ -fluoro-7 $\alpha$ -{5-[methyl-(7,7,8,8,9,9,10,10,10-  
 nonafluorodecyl)amino]pentyl}estra-1,3,5(10)-triene-3,17 $\beta$ -diol, 11 $\beta$ -fluoro-  
 17 $\alpha$ -methyl-7 $\alpha$ -{5-[methyl-(8,8,9,9,9-pentafluorononyl)amino]-pentyl}estra-  
 1,3,5(10)-triene-3,17 $\beta$ -diol, 17 $\beta$ -hydroxy-14 $\alpha$ ,15 $\alpha$ -methylene-androst-4-en-3-  
 one, 17 $\beta$ -hydroxy-7 $\alpha$ -methyl-14 $\alpha$ ,15 $\alpha$ -methylene-androst-4-en-3-one, 4-  
 chloro-17 $\beta$ -hydroxy-14 $\alpha$ ,15 $\alpha$ -methylene-androst-4-en-3-one, 4,17 $\beta$ -  
 dihydroxy-14 $\alpha$ ,15 $\alpha$ -methylene-androst-4-en-3-one, 17 $\beta$ -hydroxy-14 $\alpha$ ,15 $\alpha$ -  
 methylene-androsta-1,4-dien-3-one, 4-chloro-17 $\beta$ -hydroxy-14 $\alpha$ ,15 $\alpha$ -

methylene-androsta-1,4-dien-3-one, 4-chloro-17 $\beta$ -hydroxy-14 $\alpha$ ,15 $\alpha$ -methylene-estr-4-en-3-one, 7 $\beta$ -hydroxy-7 $\alpha$ -methyl-14 $\alpha$ ,15 $\alpha$ -methylene-estr-4-en-3-one, 17 $\beta$ -hydroxy-14 $\alpha$ ,15 $\alpha$ -methylene-estr-4-en-3-one, 4,17 $\beta$ -dihydroxy-14 $\alpha$ ,15 $\alpha$ -methylene-estr-4-en-3-one, 17 $\beta$ -hydroxy-14 $\alpha$ ,15 $\alpha$ -methylene-estra-4,9,11-trien-3-one, 3-ethyl-17 $\beta$ -hydroxy-14 $\alpha$ ,15 $\alpha$ -methylene-gon-4-en-3-one, 17 $\alpha$ - $\beta$ -hydroxy-17 $\alpha$ -homoandrosta-4,15-dien-3-one, 1''-mesyl-17 $\alpha$ -(trifluoromethyl)-1'H-pyrazol[4'',5':2,3]androst-4-en-17 $\beta$ -ol.

22. (Currently Amended) ~~Use of a pharmaceutical preparation according to Claim 1, for the production of a peroral pharmaceutical agent~~ A method for inhibiting at least one intestinal enzyme and/or at least one intestinal efflux system comprising administering a pharmaceutical preparation according to Claim 1, to a patient in need thereof.

23. (Currently amended) ~~Use of a pharmaceutical preparation~~ A method according to claim 22, wherein at least one intestinal enzyme originates from the group of 17 $\beta$ -hydroxy-steroid-dehydrogenases and/or cytochrome-P450-monooxygenases.

24. (Currently amended) ~~Use of a pharmaceutical preparation~~ A method according to claim 23, wherein ~~at least one~~ the intestinal enzyme is 17 $\beta$ -HSD 2 and/or originates from the group of cytochrome-P450-3A-monooxygenases.

25. (Currently amended) ~~Use of a pharmaceutical preparation~~ A method

according to claim 22, wherein at least one intestinal efflux system is a P-gp-transporter.

26-27 (Cancel)

28. (New) A pharmaceutical composition according to claim 1, comprising

- a) 3,6 g Cremophor<sup>®</sup>EL, 400 mg Transcutol<sup>®</sup>P, 1,0 g Miglyol<sup>®</sup> 812 or
- b) 3,6 g Cremophor<sup>®</sup>EL, 400 mg Imwitor<sup>®</sup> 308, 1,0 g Miglyol<sup>®</sup> 812 or
- c) 3,6 g Cremophor<sup>®</sup>RH, 400 mg Transcutol<sup>®</sup>P, 1,0 g Miglyol<sup>®</sup> 812 or
- d) 3,6 g Estax<sup>®</sup> 54, 400 mg Transcutol<sup>®</sup>P, 1,0 g Miglyol<sup>®</sup> 812 or
- e) 3,6 g Estax<sup>®</sup> 54, 400 mg Imwitor<sup>®</sup> 308, 1,0 g Miglyol<sup>®</sup> 812 or
- f) 3,6 g Estax<sup>®</sup> 54, 400 mg Transcutol<sup>®</sup>P, 1,0 g refined castor oil or
- g) 3,6 g Estax<sup>®</sup> 54, 400 mg Transcutol<sup>®</sup>P, 1,0 g Ethyloleat or
- h) 3,6 g Estax<sup>®</sup> 54, 400 mg Polyethylenglykol, 1,0 g Miglyol<sup>®</sup> 812 or
- i) 3,6 g Cremophor<sup>®</sup>RH, 400 mg Transcutol<sup>®</sup>P, 1,0 g refined castor oil or
- j) 3,6 g Cremophor<sup>®</sup>RH, 400 mg Transcutol<sup>®</sup>P, 1,0 g Ethyloleat or
- k) 3,6 g Cremophor<sup>®</sup>EL, 400 mg Transcutol<sup>®</sup>P, 1,0 g refined castor oil or
- l) 3,6 g Cremophor<sup>®</sup>EL, 400 mg Transcutol<sup>®</sup>P, 1,0 g Ethyloleat or
- m) 3,6 g Cremophor<sup>®</sup>EL, 400 mg Imwitor<sup>®</sup> 308, 1,0 g Ethyloleat.

29. (New) A pharmaceutical composition according to claim 9, wherein said steroid is:

- a) 11 $\beta$ -Fluoro-7 $\alpha$ -(5-[methyl-(7,7,8,8,9,9,10,10,10-nonafluorodecyl)-amino]pentyl)estra-1,3,5(10)-trien-3,17 $\beta$ -diol,

- b) Estra-1,3,5(10)-trien-3,17 $\beta$ -diol or
- c) 11 $\beta$ -Fluoro-7 $\alpha$ -{5-[methyl-(4, 4, 5, 5, 5-pentafluoropenty-9-sulfanyl)-propyl}l)-amino]pentyl}estra-1,3,5(10)-trien-3,17 $\beta$ -diol.